Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Health systems and care delivery

Topic: Risk, prevention and care in population studies

Plain-language summary

Abstract There is limited information regarding Alzheimer’s Disease and Related Dementia Diagnosis (ADRD) in Puerto Rico (PR), making it difficult to draw comparisons of the quality of care for people with ADRD between PR and the US mainland. In fact, data from the Mapping Medicare Disparities by Population Tool from Medicare only shows prevalence rates for fee-for-service Medicare enrollees. Given that about 90% of PR beneficiaries are enrolled in Medicare Advantage (MA), these rates may not reflect the full extent of older adults with ADRD on the island. Thus, the purpose of the study was to compare ADRD prevalence rates among Hispanic MA enrollees in PR to those of their US mainland counterparts. We used 20% Medicare beneficiaries (carrier file claims) and applied up to one-year lookback period. We focused on adults who were 65 and older. Our study sample included 123,609 and 547,978 Hispanic MA enrollees in PR and the US mainland in 2019. Approximately, 54% and 56% of enrollees in PR and the US mainland were female. The ADRD rates were 15% compared to 9% for PR and enrollees in the mainland. Our results show that MA enrollees in PR have six percentage points higher ADRD rates than their US counterparts. This highlights the importance of reporting ADRD rates, including MA beneficiaries. Further research on the characteristics and healthcare utilization for the people with ADRD in PR is required. This information is needed to improve the care and supports for people with ADRD and their caregivers (ASPE, 2022).

What this study adds

Evidence grade: Low

The record lists 123,609 participants. This study found that Medicare Advantage enrollees in Puerto Rico had a higher rate of Alzheimer's disease and related dementias diagnosis (15%) compared to mainland US counterparts (9%). It does not test any treatment, cure, or prevention for Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Rivera‐Hernandez, M., Liao, Y., Lee, Y., & Crowe, M. G. (2025). Prevalence of ADRD Among Medicare Advantage Enrollees in Puerto Rico Compared to US Counterparts. Innovation in Aging. https://doi.org/10.1093/geroni/igaf122.1500

Vancouver

Rivera‐Hernandez M, Liao Y, Lee Y, Crowe MG. Prevalence of ADRD Among Medicare Advantage Enrollees in Puerto Rico Compared to US Counterparts. Innovation in Aging. 2025. doi:10.1093/geroni/igaf122.1500.

BibTeX

@article{riverahernandez2025-5cab8fcb,
  author  = {Rivera‐Hernandez, Maricruz and Liao, Yanru and Lee, Yoojin and Crowe, Michael G.},
  title   = {{Prevalence of ADRD Among Medicare Advantage Enrollees in Puerto Rico Compared to US Counterparts}},
  journal = {Innovation in Aging},
  year    = {2025},
  doi     = {10.1093/geroni/igaf122.1500},
  url     = {https://doi.org/10.1093/geroni/igaf122.1500}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This study found that Medicare Advantage enrollees in Puerto Rico had a higher rate of Alzheimer's disease and related dementias diagnosis (15%) compared to mainland US counterparts (9%). It does not test any treatment, cure, or prevention for Alzheimer's disease.

Study details

How this study scored 38/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 4 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 1 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 2 of 4; Institution's track record 1 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 1 of 2; Free to read 2 of 2. Total 38 of 100.38 of 100 points earned62 not earned

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Innovation in Aging)
Journal's citation record 0 / 4 Innovation in Aging: journal h-index 48 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 4 / 4 123,609 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 1 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.3 citations a year over 3 year(s) since 2025
Impact for its field and year 1 / 6 Cited 0.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Michael G. Crowe: h-index 41 (OpenAlex, whole career)
Institution's track record 1 / 3 Brown University: institution h-index 1,120 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 2 / 2 Free to read
Total 38 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Health systems and care delivery from nearby years

Also tagged “palliative”

858 studies in the library carry the topic tag “palliative”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 858 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Health systems and care delivery

See all studies in Health systems and care delivery →